脐带血输注对复发/难治老年髓系肿瘤患者抗肿瘤免疫微环境的调节作用研究
杜晨霄 ,罗诗琴 ,滕广帅 ,张会勤 ,王艳 ,李艳旗 ,张宇卉 ,白洁 *
作者信息
- 天津医科大学第二医院血液科,天津 300211
*通信作者
摘要
背景与目的 高危老年复发/难治髓系肿瘤(R/R MN)最佳治疗尚无统一标准,目前主要以挽救化疗为主,但该类患者或因不耐受强化疗而无法桥接异基因造血干细胞移植。脐带血(UCB)应用在高危 R/R MN 治疗中的探索越来越多,但 UCB 回输后免疫变化尚不明朗。本研究旨在探索 UCB 输注对老年 R/R MN 患者疗效的改善和免疫微环境的变化规律。 方法 回顾性分析2022 年12 月至2024 年12 月天津医科大学第二医院血液科应用 UCB 回输的年龄>65 岁的 R/R MN 患者 11 例,所有患者均行 2个周期挽救化疗联合UCB输注治疗。 临床疗效分析主要评估总体完全缓解(CR)率及总生存期(OS)。通过对比脐血输注前1周及输注后 1、3、6 个月免疫细胞功能及细胞因子水平变化评估免疫微环境改变。 结果 11 例患者中,有 3 例达到 CR,CR 率为 27. 27% 。截止到中位随访时间,4 例(36. 36%)仍存活。 回输后 1 个月CD8+ T 细胞、自然杀伤(NK)细胞、NK/ T 细胞比例较前明显上升,且 3、6 个月复查未见明显降低;CD8+效应记忆 T 细胞(CD8+TEM)回输后上述各时间节点均持续上升;Treg 细胞回输后1个月内较前明显下降,3 个月内恢复至回输前水平。CD19+ B 于回输后1个月达到峰值,于 6个月内缓慢回落至回输前;余免疫细胞功能回输前后无明显变化。回输后白细胞介素(IL)-2、干扰素-γ(IFN-γ)、肿瘤坏死因子-α(TNF-α)水平持续上升,IL-4、转化生长因子-β(TGF-β)水平持续下降,IL-10 水平于回输后 1 个月降至最低,后于 6 个月内缓慢升至术前水平。 结论 UCB 回输可提高高危 R/R MN 患者缓解率及生存期。 UCB输注后 R/R MN 患者免疫微环境变化以免疫耐受解除、抗肿瘤活性增加为主,但该有利变化维持时间不超过6个月。
Study on the regulatory effect of umbilical cord blood transfusion on the antitumor immune microenvironment in elderly patients with recurrent/refractory myeloid tumors
Chenxiao DU , Shiqin LUO , Guangshuai TENG , Huiqin ZHANG , Yan WANG , Yanqi LI , Yuhui ZHANG , Jie BAI *
Author Information
- Department of Hematology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China
*Corresponding author
Abstract
Background and objective There is no unified standard for the optimal treatment of high-risk elderly patients with relapse/refractory myeloid neoplasms (R/R MN). Currently, salvage chemotherapy is the main treatment,but some patients cannot bridge to allogeneic hematopoietic stem cell transplantation due to intolerance to intensive chemotherapy. The application of umbilical cord blood (UCB) in the treatment of high-risk R/R MN has been increasingly explored, but the immune changes after UCB transfusion remain unclear. This study aims to investigate the efficacy of UCB transfusion in elderly R/R MN patients and the changing rules of the immune microenvironment. Methods A retrospective analysis was performed on 11 elderly patients (aged>65 years) with R/R MN who received UCB transfusion in the Department of Hematology, The Second Hospital of Tianjin Medical University from December 2022 to December 2024. All patients underwent 2 cycles of salvage chemotherapy combined with UCB transfusion. Clinical efficacy was mainly evaluated by the overall complete response (CR) rate and overall survival (OS). The changes of immune microenvironment were evaluated by comparing the immune cell function and cytokine levels before umbilical cord blood transfusion and at 1,3 and 6 months after transfusion. Results Among the 11 patients, 3 achieved CR, with an overall CR rate of 27. 27% . At the median follow-up time, 4 (36. 36%) patients remained alive. One month after reinfusion, the proportions of CD8+ T cells, natural killer (NK) cells, and NK/T cells showed a significant increase compared to the baseline level, with no significant decrease observed in follow-up examinations at 3 and 6 months. CD8+ effector memory T cells (CD8+ TEM)maintained a continuous upward trend at all time points post-reinfusion. Treg cells exhibited a marked decline within one month after reinfusion but recovered to pre-reinfusion levels within three months. CD19+ B cells peaked one month post-reinfusion and gradually declined to pre-reinfusion levels by six months. No significant changes were observed in the functional status of other immune cells before and after reinfusion. After reinfusion, the levels of interleukin(IL)-2 (IL-2), interferon-γ (IFN-γ), and tumor necrosis factor-α(TNF-α)continued to rise, while the levels of IL-4 and transforming growth factor-β (TGF-β) remained persistently decreased. The level of IL-10 reached its lowest point one month after reinfusion and then gradually increased to preoperative levels within six months.Conclusion UCB transfusion can improve the response rate and survival of high-risk R/ R MN patients. The immune microenvironment changes in R/R MN patients after UCB transfusion are mainly characterized by the release of immune tolerance and enhanced antitumor activity, but these beneficial changes last no more than 6 months.
